Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 277

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Autologous B7-H3 Chimeric Antigen Receptor T Cells for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T cells for the Treatment of Patients with Recurrent Platinum Resistant or Refractory Epithelial Ovarian Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Genetically Engineered Cells (FSHCER T cells) for the Treatment of Recurrent Platinum-resistant or Platinum-refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Status: Active
Location: See ClinicalTrials.gov
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Location: See ClinicalTrials.gov
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov